Heitkamp & Thumann Group makes strategic investment in Cohero Health
Düsseldorf, Germany – 4 November 2016 - The Heitkamp & Thumann Group, one of the world's leading manufacturers of precision-formed metal and plastic components, has made a strategic investment in U.S.-based Cohero Health Inc.
Cohero Health is a leading player in the rapidly growing digital health market with a focus on digital management systems in respiratory care.
“We are glad to have the Heitkamp & Thumann Group as an investor. This decision strengthens our existing successful partnership”, says Melissa Manice, Co-Founder and CEO of Cohero Health.
H&T Presspart, a division of the Heitkamp & Thumann Group and Cohero Health started collaborating on developing a connected inhaler for tracking and improving medication adherence over two years ago, and announced its completion in April 2016.
”Our partnership with Cohero Health allows us to provide our customers with innovative connected product solutions, helping them taking advantage of the great potential of the new era of Internet of Things”, explains Christian Diemer, CEO Heitkamp & Thumann Group.
About the Heitkamp & Thumann Group:
The Heitkamp & Thumann Group is a leading global partner for the development and supply of world-class precision-formed components in both metal and plastic. The family-owned group comprises more than 20 small and medium-sized enterprises located in 9 different countries and employing some 2.000 people.
Nils Hubert, Director HR & Public Affairs | email@example.com | Phone: +49 171 8 111 819
About Cohero Health, Inc:
Cohero Health is a digital health company developing innovative tools and technologies to improve respiratory care, reduce avoidable costs, and optimize medication. The company’s connected devices and mobile applications actively engage and empower respiratory patients by measuring lung function and tracking adherence. Based in New York City, the company is a member of StartUp Health, Springboard Enterprises, and Grand Central Tech. The company’s platform has been used by pulmonary patients in over 25 commercial deployments reaching over 1M covered lives.
Mike Marett | firstname.lastname@example.org | Phone: +1 917-509-5011